Suchergebnisse - "Polin, Lisa"

PubPharm (6)

1

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro

enthalten in: Biochemical pharmacology | 2024

von Hurrish, K. | Su, Y. | Patel, S. | +26

UpdateOf: Res Sq. 2023 Apr 28;:. - PMID 37162954

2

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis

enthalten in: Research square | 2023

von Hurrish, K. | Su, Y. | Patel, S. | +24

UpdateIn: Biochem Pharmacol. 2023 Dec 10;220:115981. - PMID 38081370

3

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

enthalten in: Haematologica | 2021

von Li, X. | Su, Y. | Hege, K. | +15

4

Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation

enthalten in: Cancers | 2020

von Liu, F. | Kalpage, H. | Wang, D. | +13

5

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia

enthalten in: Signal transduction and targeted therapy | 2020

von Luedtke, D. | Su, Y. | Ma, J. | +10

6

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2019

von Ma, J. | Zhao, S. | Qiao, X. | +12

CommentIn: Clin Cancer Res. 2019 Nov 15;25(22):6567-6569. - PMID 31515455

1
[1]